LONDON, March 6, 2026 /PRNewswire/ -- The "Exosome Diagnostic and Therapeutics Market – Growth, Share, Opportunities & Competitive Analysis, 2025 – 2032" report has been added to the Credence Research Inc. offering.

The global Exosome Diagnostic and Therapeutics Market is projected to grow from USD 41.3 Million in 2025 to an estimated USD 401.70 Million by 2032, registering an exceptional CAGR of 31.10% during the forecast period. The market's rapid expansion reflects growing demand for non-invasive diagnostic methods, rising adoption of precision medicine, and the increasing role of exosomes as promising carriers for targeted therapeutic delivery across oncology, neurology, and other disease areas.

Scope & Segmentation – Exosome Diagnostic and Therapeutics Market

The report provides a comprehensive analysis of the global Exosome Diagnostic and Therapeutics Market, covering revenue forecasts from 2025 to 2032. It evaluates market drivers, trends, challenges, opportunities, competitive landscape, and regional dynamics influencing the adoption of exosome-based technologies. The study examines advances in non-invasive diagnostics, liquid biopsy applications, drug delivery systems, isolation platforms, and translational research efforts supporting exosome-based innovation.

The report further assesses the role of exosomes in disease detection, treatment monitoring, precision medicine, and therapeutic delivery. It also analyzes the growing integration of exosome technologies across oncology, cardiovascular care, dermatology, neurology, and other medical applications, while highlighting the impact of R&D investments and commercialization partnerships on market development.

The exosome diagnostic and therapeutics market is segmented based on type, product & service, source, application, end user, and geography.

• By Type, the market includes Exosome Diagnostics and Exosome Therapeutics.
• By Product & Service, the market covers Instruments & Services and Kits & Reagents.
• By Source, the market includes Stem Cells, Blood & Blood Plasma, Urine, and Other Sources.
• By Application, the market includes Cancer, Dermatological Diseases, Musculoskeletal Disorders, Cardiovascular Diseases, and Other Applications.
• By End User, the market includes Hospitals and Clinics & Physician Settings.
• By Geography, the market is analyzed across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, with country-level coverage for major markets including the U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, China, Japan, India, South Korea, Southeast Asia, Brazil, Argentina, GCC Countries, and South Africa.

Request your sample report today & start making informed decisions powered by Credence Research Inc.! - https://www.credenceresearch.com/report/exosomes-diagnostic-and-therapeutic-market

Why This Report Matters

• This report provides a detailed view of one of the fastest-evolving segments in advanced diagnostics and therapeutics, with the market projected to expand nearly tenfold by 2032.
• It helps decision-makers understand how liquid biopsies, personalized medicine, biomarker discovery, and exosome-enabled drug delivery are reshaping clinical diagnostics and treatment pathways.
• The study highlights regional growth opportunities across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, helping companies assess expansion potential in both mature and emerging healthcare ecosystems.
• For CXOs, investors, biotech innovators, and diagnostic developers, this report delivers actionable intelligence to guide R&D strategy, commercialization priorities, partnership development, and long-term market positioning.

Market Overview:

• Industry Landscape and Value Chain Assessment
• Supply-Side Evaluation
• Demand-Side Evaluation
• Stakeholder Mapping
• Porter's Five Forces Review
• PESTLE Environment Assessment
• Market Forecast and Future Direction
• Short-Term Forecast (0–2 Years)
• Mid-Term Forecast (3–5 Years)
• Long-Term Forecast (5–10 Years)
• Market Entry and Expansion Strategy

Market Insights:

• Customer and End-User Analysis
• Customer Experience Comparison
• Growth Opportunity Assessment
• Channel and Distribution Review
• Pricing Movement Analysis
• Regulatory and Compliance Review
• Sustainability and ESG Assessment
• Risk and Disruption Analysis
• Investment Return and Cost Evaluation

Key Attributes

Regional Growth Reflects Expanding Research, Precision Medicine Adoption, and Healthcare Investment

• North America holds the largest share of the exosome diagnostic and therapeutics market, accounting for approximately 42% of global revenue. The region's dominance is supported by strong investments in biotechnology, the presence of advanced research institutions, early adoption of innovative diagnostic technologies, and high demand for precision medicine solutions. The U.S. remains the principal growth engine, backed by extensive funding and a strong translational research ecosystem.
• Europe contributes around 27% of the global market and benefits from robust academic research, public support for personalized medicine, and growing use of liquid biopsy technologies. Countries such as Germany, the U.K., and France are central to regional market expansion, supported by research collaborations and increasing use of exosome-based technologies in oncology and rare disease applications.

Market Challenges Include High Development Costs, Regulatory Complexity, and Technical Standardization Issues

Despite strong long-term growth prospects, the exosome diagnostic and therapeutics market faces several operational and commercial barriers. One major constraint is the high cost of research and development, as advanced exosome isolation, characterization, and therapeutic development require sophisticated technologies, specialized expertise, and lengthy validation cycles.

The market also faces complex and evolving regulatory pathways. Regulatory agencies are still refining standards for exosome-based diagnostics and therapeutics, creating uncertainty around product validation, quality control, and commercialization timelines. This can delay approvals and raise entry barriers for emerging firms.

In addition, technical challenges in exosome isolation and characterization continue to affect scalability and reproducibility. Variability in purity, yield, and analytical standardization limits seamless integration into routine clinical workflows. Limited awareness among healthcare providers and end users further slows broader adoption, particularly in cost-sensitive markets.

Future Outlook

The Exosome Diagnostic and Therapeutics Market is poised for transformative growth through 2032, fueled by rising demand for non-invasive diagnostics, accelerating adoption of personalized medicine, and increasing exploration of exosomes as natural drug delivery vehicles. Liquid biopsy applications are expected to remain a major catalyst, particularly in oncology and neurology, where early detection and treatment monitoring are critical.

Continued advances in exosome isolation, analysis, and therapeutic engineering will define the next phase of market development. As regulatory frameworks mature and commercialization pathways become clearer, companies that prioritize scalable technologies, strong partnerships, and clinically relevant applications will be best positioned to capture the expanding opportunity across global healthcare markets.

Competitive Landscape

The exosome diagnostic and therapeutics market is characterized by a competitive environment shaped by innovation, strategic collaborations, and rapid technology development. Established participants and emerging firms are actively expanding their capabilities in exosome isolation, biomarker discovery, liquid biopsy development, and therapeutic applications. Companies with strong R&D pipelines, scalable platforms, and precision medicine alignment are strengthening their competitive positions.

The market remains moderately fragmented, with a mix of established players, niche innovators, and academic spin-offs contributing to a dynamic innovation landscape. High R&D intensity, regulatory hurdles, and commercialization complexity continue to differentiate companies based on technical depth, quality control, and translational execution.

Key Player Analysis

• NanoSomix, Inc.
• Capricor Therapeutics, Inc.
• NX Pharmagen, Inc.
• Sistemic Ltd
• Thermo Fisher Scientific, Inc.
• Malvern Instruments Ltd
• Exiqon A/S
• Exosome Diagnostic, Inc.
• Aethlon Medical, Inc.
• System Biosciences, Inc.

Recent Industry Developments

• In September 2025, mdxhealth announced the closing of its acquisition of Bio-Techne's Exosome Diagnostics (ExoDx) business, including the ExoDx Prostate (EPI) test, a CLIA-certified clinical laboratory, and related assets.
• In July 2024, AcouSort AB initiated two new collaborations in the cell therapy space, one with a U.S.-based company and another with a European company, both beginning with three-month leases of the AcouWash system.

Report Coverage

The research report offers an in-depth analysis based on Type, Product & Service, Source, Application, and End User. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, and the primary drivers and constraints influencing market expansion.

The study further explores market dynamics, regulatory developments, technological advancements, and the impact of broader economic factors on growth. It also provides strategic recommendations for both new entrants and established companies seeking to navigate the evolving exosome diagnostics and therapeutics landscape.

Download Sample Report - https://www.credenceresearch.com/report/exosomes-diagnostic-and-therapeutic-market

Related Reports –

Antipsychotic Drugs Market https://www.credenceresearch.com/report/antipsychotic-drugs-market

Arteriotomy Closure Devices Market https://www.credenceresearch.com/report/arteriotomy-closure-devices-market

Articaine Hydrochloride Market https://www.credenceresearch.com/report/articaine-hydrochloride-market

Artificial Intelligence In IVD Market https://www.credenceresearch.com/report/ai-in-vitro-diagnostics-market

Artificial Blood Vessels Market https://www.credenceresearch.com/report/artificial-blood-vessels-market

Artificial Intelligence In Pharmaceutical Market https://www.credenceresearch.com/report/artificial-intelligence-ai-in-pharmaceutical-market

Artificial Disc Market https://www.credenceresearch.com/report/artificial-disc-market

Artificial Heart Market https://www.credenceresearch.com/report/artificial-heart-market

Artificial Intelligence In Diagnostics Market https://www.credenceresearch.com/report/artificial-intelligence-ai-in-diagnostics-market

Aseptic Transfer System Market https://www.credenceresearch.com/report/aseptic-transfer-system-market

About Us

Credence Research Inc is a global market intelligence and consulting firm founded in 2015. It delivers deep market insights, quantitative analysis, and strategic guidance to business leaders, investors, governments, NGOs, and non-profit groups worldwide. The company helps organizations evaluate markets, understand trends, reduce risk, and make data-driven decisions that support growth and competitive strategy. Credence Research is known for rigorous research methods and comprehensive analytics.

The firm produces detailed reports covering market size, forecasts, growth drivers, trends, and competitive landscapes across many industries. Each report often includes frameworks like PESTLE and Porter's Five Forces to give a complete view of market dynamics and future potential. Credence Research also provides tailored consulting services, due diligence support, go-to-market planning, and pre-IPO research to strengthen client strategies and investment narratives. Its insights come from both primary and secondary research, expert interviews, and advanced data modelling. The firm's client base spans Europe, the Americas, Asia-Pacific, and the Middle East/Africa.

To find out more, visit www.credenceresearch.com or follow us on X.com, LinkedIn and Facebook

Contact Us –

Credence Research Inc,

Tower C-1105, S 25,

Akash Tower,

Vishal Nagar,

Pimple Nilakh, Haveli,

Pune – 411027, India

USA: +1-888-600-6441

Email: sales@credenceresearch.com 

Visit Our Website: https://www.credenceresearch.com/

Logo: https://mma.prnewswire.com/media/2562161/Credence_Research_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/exosome-diagnostic-and-therapeutics-market-to-reach-usd-401-70-million-by-2032-amid-rapid-advances-in-liquid-biopsy-precision-medicine-and-exosome-based-drug-delivery--credence-research-302706326.html

Zalando hat 2025 kräftig zugelegt und seine eigenen Ziele am oberen Ende der Spannen erreicht. Der Umsatz des im DAX notierten Online-Modehändlers stieg um 16,8 Prozent auf 12,35 Milliarden Euro und lag damit leicht über den Markterwartungen. Das Bruttowarenvolumen (GMV) kletterte um 14,7 Prozent auf 17,56 Milliarden Euro. Rückenwind bekam das Geschäft vor allem durch die Übernahme des Konkurrenten About You sowie den verstärkten Einsatz Künstlicher Intelligenz in Vertrieb und Plattformsteuerung.

Operativ verbesserte sich Zalando ebenfalls: Das bereinigte Ergebnis vor Zinsen und Steuern (EBIT) erhöhte sich auf 591 Millionen Euro nach 511 Millionen Euro im Vorjahr, die Marge blieb mit 4,8 Prozent stabil und leicht über den Analystenprognosen. Unter dem Strich sank der Gewinn jedoch auf 213 Millionen Euro von zuvor 251 Millionen Euro und verfehlte damit die Erwartungen. Für das laufende Jahr stellt das Management ein weiteres Wachstum von 12 bis 17 Prozent bei GMV und Umsatz in Aussicht; das bereinigte EBIT soll auf 660 bis 740 Millionen Euro steigen. Die mittelfristigen Ziele bis 2028 – jährliche Zuwächse von 8 bis 13 Prozent bei Umsatz und GMV sowie eine EBIT-Marge von 6 bis 8 Prozent – wurden bestätigt, die angepeilten jährlichen Synergien aus der About-You-Übernahme von 100 Millionen Euro sollen bereits 2028 und damit ein Jahr früher erreicht sein.

An der Börse sorgte vor allem die Kapitalmarktpolitik für Auftrieb. Der Konzern kündigte ein Aktienrückkaufprogramm von bis zu 300 Millionen Euro an, das bis Ende Juli laufen soll. Die Aktie legte im Tagesverlauf zweistellig zu und notierte zeitweise rund elf Prozent höher bei 22,35 Euro. Damit reagierte der Markt positiv auf die Kombination aus besser als erwarteten operativen Kennzahlen, bestätigtem Wachstumskurs und der Ankündigung, überschüssiges Kapital an die Anteilseigner zurückzuführen – obwohl die Zalando-Papiere seit Jahresbeginn deutlich im Minus liegen und in den vergangenen zwölf Monaten rund ein Drittel an Wert verloren haben. Analysten hoben neben dem Rückkauf insbesondere die Rolle von KI und das Konzept des sogenannten Agentic Commerce als nächste Entwicklungsstufe des Onlinehandels hervor.

Überschattet werden die guten Zahlen von strukturellen Einschnitten im Logistiknetz. Im Zuge der Integration von About You will Zalando vier Logistikzentren in Europa schließen, darunter den Standort Erfurt mit rund 2.700 Beschäftigten. Co-Chef David Schröter sprach von einer der schwersten, zugleich aber notwendigen Entscheidungen, um die Kapazitäten an den künftigen Wachstumsbedarf anzupassen. Das Unternehmen verhandelt nach eigenen Angaben mit dem Betriebsrat über einen Sozialplan, bietet Versetzungen an andere Standorte an und arbeitet mit der örtlichen Arbeitsagentur zusammen. Weitere Maßnahmen über die bereits angekündigten Schließungen hinaus soll es dem Management zufolge nicht geben; aus der Thüringer Landespolitik kommt dennoch Kritik an der Entscheidung.